

# Rupert Bartsch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4494923/publications.pdf>

Version: 2024-02-01

166  
papers

3,834  
citations

159585

30  
h-index

149698

56  
g-index

167  
all docs

167  
docs citations

167  
times ranked

5395  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC. <i>Clinical Breast Cancer</i> , 2022, 22, 223-234.	2.4	2
2	Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients. <i>British Journal of Cancer</i> , 2022, 126, 456-463.	6.4	15
3	Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response. <i>Clinical Cancer Research</i> , 2022, 28, 697-707.	7.0	17
4	Updated Austrian treatment algorithm in HER2+ metastatic breast cancer. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 63-72.	1.9	1
5	Expert Discussion: SABCS 2021. <i>Breast Care</i> , 2022, 17, 101-106.	1.4	0
6	The impact of COVID-19 on cancer care of outpatients with low socioeconomic status. <i>International Journal of Cancer</i> , 2022, 151, 77-82.	5.1	15
7	Abstract P1-02-07: Accuracy and predictive value of resection margin assessment by intraoperative frozen section after neoadjuvant therapy: An analysis of the ABCSG 24 and 34 trials. <i>Cancer Research</i> , 2022, 82, P1-02-07-P1-02-07.	0.9	0
8	Abstract P1-02-06: Prediction of Prosigna® breast cancer intrinsic subtype by immunohistochemical ER, PR and Ki67 expression. <i>Cancer Research</i> , 2022, 82, P1-02-06-P1-02-06.	0.9	0
9	Abstract P2-13-30: First interim analysis from ELEANOR: A multi-national, prospective, non-interventional study (NIS) in patients with human epidermal growth factor receptor positive (HER2+) early breast cancer observing real-life extended adjuvant treatment with neratinib. <i>Cancer Research</i> , 2022, 82, P2-13-30-P2-13-30.	0.9	0
10	Abstract P5-07-04: Comprehensive analysis of the gene rearrangements within 822 breast cancer brain metastases reveals an enrichment of cyclin dependent kinase 12 rearrangements in HER2-positive brain metastases. <i>Cancer Research</i> , 2022, 82, P5-07-04-P5-07-04.	0.9	0
11	Abstract PD4-09: Comprehensive assessment of the genomic landscape of breast cancer brain metastases reveals targetable alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitors. <i>Cancer Research</i> , 2022, 82, PD4-09-PD4-09.	0.9	0
12	The cancer survival index™ A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies. <i>Cancer Medicine</i> , 2022, 11, 3387-3396.	2.8	7
13	Effect of concomitant statin treatment in postmenopausal patients with hormone receptor-positive early-stage breast cancer receiving adjuvant denosumab or placebo: a post hoc analysis of ABCSG-18. <i>ESMO Open</i> , 2022, 7, 100426.	4.5	2
14	Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 654-674.	1.9	7
15	Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force. <i>ESMO Open</i> , 2022, 7, 100483.	4.5	3
16	The iTOP trial: Comparing immediate techniques of oncoplastic surgery with conventional breast surgery in women with breast cancer - A prospective, controlled, single-center study. <i>International Journal of Surgery</i> , 2022, 104, 106694.	2.7	4
17	Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel. <i>Oncologist</i> , 2022, 27, 722-731.	3.7	6
18	Expectations and perception of cancer treatment goals in previously untreated patients. The EXPECT trial. <i>Supportive Care in Cancer</i> , 2021, 29, 3585-3592.	2.2	4

#	ARTICLE	IF	CITATIONS
19	Results from the FeDeriCa trial: are we reducing the burden of breast cancer treatment?. <i>Lancet Oncology</i> , The, 2021, 22, 5-6.	10.7	0
20	Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110090.	3.2	9
21	ASCO 2020: highlights in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 58-61.	0.5	8
22	Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. <i>JCO Global Oncology</i> , 2021, 7, 162-172.	1.8	38
23	Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e575-e583.	2.4	7
24	PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial. <i>British Journal of Surgery</i> , 2021, 108, 308-314.	0.3	19
25	Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34. <i>British Journal of Cancer</i> , 2021, 124, 1795-1802.	6.4	3
26	ESMO 2020: highlights in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 184-187.	0.5	9
27	Impact of COVID-19 lockdown on routine oncology versus emergency care at a high volume cancer centre. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13623.	3.4	7
28	Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. <i>Oncologist</i> , 2021, 26, 835-844.	3.7	16
29	SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 247-251.	0.5	9
30	European Society for Medical Oncology 2020. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 130-131.	0.5	0
31	Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 395-405.	27.0	82
32	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	3.7	12
33	Position Paper on the Value of Extended Adjuvant Therapy with Neratinib for Early HER2+/HR+ Breast Cancer. <i>Breast Care</i> , 2021, 16, 664-676.	1.4	1
34	ASCO 2020. <i>Breast Care</i> , 2020, 15, 433-436.	1.4	0
35	Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 901-910.	4.1	18
36	Targeted Therapy Recommendations for Therapy Refractory Solid Tumors—Data from the Real-World Precision Medicine Platform MONDTI. <i>Journal of Personalized Medicine</i> , 2020, 10, 188.	2.5	7

#	ARTICLE	IF	CITATIONS
37	Oncological care organisation during COVID-19 outbreak. ESMO Open, 2020, 5, e000853.	4.5	29
38	Position statement of the Austrian Society for Hematology and Medical Oncology on the use of molecular diagnostics in solid tumors. Memo - Magazine of European Medical Oncology, 2020, 13, 450-452.	0.5	1
39	Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 545-555.	2.8	5
40	Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metaanalysis with meta-regression. Cancer Treatment Reviews, 2020, 88, 102046.	7.7	39
41	ESMO 2019: breast cancer. Memo - Magazine of European Medical Oncology, 2020, 13, 147-149.	0.5	1
42	Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer. European Journal of Cancer, 2020, 135, 150-158.	2.8	10
43	Circumnavigating the challenges of COVID-19 in oncology. Memo - Magazine of European Medical Oncology, 2020, 13, 135-138.	0.5	2
44	Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2 <sup>+</sup> advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT. Breast, 2020, 50, 64-70.	2.2	12
45	Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSCG 34). European Journal of Cancer, 2020, 132, 43-52.	2.8	24
46	Current Treatment Strategies in Breast Cancer Brain Metastases. , 2020, , 267-279.		0
47	Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. ESMO Open, 2020, 5, e000880.	4.5	4
48	ASCO 2019: highlights in HER2-positive metastatic breast cancer. Memo - Magazine of European Medical Oncology, 2019, 12, 308-311.	0.5	1
49	Luminal Metastatic Breast Cancer. Breast Care, 2019, 14, 99-101.	1.4	1
50	An update on immunotherapy in breast cancer. Memo - Magazine of European Medical Oncology, 2019, 12, 63-66.	0.5	0
51	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b <sup>1/2</sup> trial. Lancet Oncology, The, 2019, 20, 371-382.	10.7	327
52	Optimizing care for geriatric cancer patients: the greatest challenge in medical oncology?. Memo - Magazine of European Medical Oncology, 2019, 12, 288-289.	0.5	0
53	An update from the 2019 ASCO Annual Meeting. Memo - Magazine of European Medical Oncology, 2019, 12, 285-285.	0.5	1
54	Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases. Clinical Cancer Research, 2019, 25, 2737-2744.	7.0	34

#	ARTICLE	IF	CITATIONS
55	Impact of Breast Surgery in Primary Metastasized Breast Cancer. <i>Annals of Surgery</i> , 2019, 269, 1163-1169.	4.2	130
56	My burning issues in the neoadjuvant treatment for breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 27-30.	0.5	0
57	ESMO 2017â€™my personal highlights. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 77-79.	0.5	0
58	Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial). <i>BMC Cancer</i> , 2018, 18, 1074.	2.6	12
59	Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 727-738.	3.3	21
60	ASCO 2018: highlights in HER2-positive metastatic breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 280-283.	0.5	18
61	Current concepts and future directions in neoadjuvant chemotherapy of breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 199-203.	0.5	18
62	SABCS 2017: update on chemotherapy, targeted therapy, and immunotherapy. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 204-207.	0.5	3
63	CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. <i>ESMO Open</i> , 2018, 3, e000368.	4.5	35
64	Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastasesâ€™ development and validation of the LabBM score. <i>Neuro-Oncology</i> , 2017, 19, now290.	1.2	26
65	Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 3676-3683.	7.0	29
66	Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: A retrospective analysis of 624 patients. <i>European Journal of Cancer Care</i> , 2017, 26, e12707.	1.5	25
67	Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases. <i>European Radiology</i> , 2017, 27, 3167-3173.	4.5	80
68	Ribociclib: a valuable addition to treatment options in breast cancer?. <i>ESMO Open</i> , 2017, 2, e000246.	4.5	3
69	Biosimilars in the Treatment of Breast Cancer. <i>Breast Care</i> , 2017, 12, 192-194.	1.4	1
70	Adverse Events of Trastuzumab Emtansine (T-DM1) in the Treatment of HER2-Positive Breast Cancer Patients. <i>Breast Care</i> , 2017, 12, 401-408.	1.4	28
71	Highlights from the 2017 St. Gallen Breast Cancer Consensus. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 173-174.	0.5	2
72	My personal highlights of ESMO 2016. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 46-47.	0.5	0

#	ARTICLE	IF	CITATIONS
73	To print or not to print. Memo - Magazine of European Medical Oncology, 2017, 10, 1-2.	0.5	0
74	Investigating the prediction value of multiparametric magnetic resonance imaging at 3ÅT in response to neoadjuvant chemotherapy in breast cancer. European Radiology, 2017, 27, 1901-1911.	4.5	59
75	ASCO 2017: highlights in breast cancer. Memo - Magazine of European Medical Oncology, 2017, 10, 228-232.	0.5	13
76	Primary tumor sidedness associates with prognosis of patients with brain metastases of colorectal cancer.. Journal of Clinical Oncology, 2017, 35, 3562-3562.	1.6	1
77	Extravasation emergencies: state-of-the-art management and progress in clinical research. Memo - Magazine of European Medical Oncology, 2016, 9, 226-230.	0.5	15
78	Recent developments and translational aspects in targeted therapy for metastatic breast cancer. ESMO Open, 2016, 1, e000036.	4.5	1
79	Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. ESMO Open, 2016, 1, e000024.	4.5	152
80	I-SPY 2: optimising cancer drug development in the 21st century. ESMO Open, 2016, 1, e000113.	4.5	11
81	Rationale of an economically driven PD1 biomarker development in lung cancer“an academic dilemma. Memo - Magazine of European Medical Oncology, 2016, 9, 109-110.	0.5	1
82	ASCO 2016: highlights in breast cancer. Memo - Magazine of European Medical Oncology, 2016, 9, 211-214.	0.5	4
83	Prognostic impact of breast cancer subtypes in elderly patients. Breast Cancer Research and Treatment, 2016, 157, 91-99.	2.5	22
84	Pathological complete remission and long-term outcome“what do we know in 2016?. Lancet Oncology, The, 2016, 17, 693-694.	10.7	3
85	Prognostic value of <sc>HMGB</sc>1 in early breast cancer patients under neoadjuvant chemotherapy. Cancer Medicine, 2016, 5, 2350-2358.	2.8	34
86	Diffusion“weighted MRI of breast lesions: a prospective clinical investigation of the quantitative imaging biomarker characteristics of reproducibility, repeatability, and diagnostic accuracy. NMR in Biomedicine, 2016, 29, 1445-1453.	2.8	46
87	Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). Journal of Neuro-Oncology, 2016, 130, 19-29.	2.9	107
88	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. ESMO Open, 2016, 1, e000066.	4.5	17
89	A welcome statement from the associate Editor-in-Chief. Memo - Magazine of European Medical Oncology, 2016, 9, 106-106.	0.5	0
90	A Cross-Sectional Study of Patients“™ Satisfaction With Totally Implanted Access Ports. Clinical Journal of Oncology Nursing, 2016, 20, 175-180.	0.6	12

#	ARTICLE	IF	CITATIONS
91	Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 70-75.	0.5	0
92	Palbociclib for the treatment of postmenopausal breast cancer – an update. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 255-263.	1.8	15
93	Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. <i>Oncolmunology</i> , 2016, 5, e1057388.	4.6	239
94	PD-L1 expression and tumor infiltrating lymphocytes (TIL) in brain metastases (BM) of small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 8563-8563.	1.6	1
95	ASCO 2015: Highlights in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 209-212.	0.5	0
96	Breast cancer brain metastases responding to lapatinib plus capecitabine as second-line primary systemic therapy. <i>Anti-Cancer Drugs</i> , 2015, 26, 579-581.	1.4	6
97	The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial. <i>British Journal of Cancer</i> , 2015, 112, 1405-1410.	6.4	68
98	CDK4/6 inhibitors in luminal breast cancer. <i>Lancet Oncology, The</i> , 2015, 16, 2-3.	10.7	7
99	Port-a-Cath® extravasation of vesicant cytotoxics: Surgical options for a rare complication of cancer chemotherapy. <i>European Journal of Surgical Oncology</i> , 2015, 41, 378-385.	1.0	27
100	Outcome of chemotherapy extravasation in a large patient series using a standardised management protocol. <i>Supportive Care in Cancer</i> , 2015, 23, 1741-1748.	2.2	23
101	Postoperative CMF Does Not Ameliorate Poor Outcomes in Women With Residual Invasive Breast Cancer After Neoadjuvant Epirubicin/Docetaxel Chemotherapy. <i>Clinical Breast Cancer</i> , 2015, 15, 505-511.	2.4	4
102	Discrepancies between ESMO and NCCN breast cancer guidelines: An Appraisal. <i>Breast</i> , 2015, 24, 513-523.	2.2	26
103	Bevacizumab: no comeback in early breast cancer?. <i>Lancet Oncology, The</i> , 2015, 16, 1001-1003.	10.7	3
104	Activity of T-DM1 in Her2-positive breast cancer brain metastases. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 729-737.	3.3	103
105	Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. <i>Annals of Oncology</i> , 2015, 26, 313-320.	1.2	251
106	Abstract P3-11-06: Bevacizumab in combination with docetaxel+trastuzumab +/- non-pegylated liposomal doxorubicin: Final results of ABCSG-32, a prospective, randomized phase II-study. , 2015, , .		3
107	Plasma PD-L1 concentration in patients with brain metastases from solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13026-e13026.	1.6	3
108	Phase II study on the efficacy and safety of lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu: Positive advanced breast cancer (CECOG LaVie Trial).. <i>Journal of Clinical Oncology</i> , 2015, 33, e11603-e11603.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Effect of laboratory parameters on prognostic value in patients with newly diagnosed brain metastases: Analysis of 1,207 cases.. Journal of Clinical Oncology, 2015, 33, e13034-e13034.	1.6	0
110	Prognostic impact of breast cancer (BC) subtype in elderly patients.. Journal of Clinical Oncology, 2015, 33, e20536-e20536.	1.6	0
111	Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer. Breast Care, 2014, 9, 6-6.	1.4	8
112	Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSCG-24). Annals of Oncology, 2014, 25, 366-371.	1.2	62
113	HER2-positive breast cancer: a new piece of the puzzle. Lancet Oncology, The, 2014, 15, 668-669.	10.7	2
114	Breast cancer brain metastases responding to primary systemic therapy with T-DM1. Journal of Neuro-Oncology, 2014, 116, 205-206.	2.9	61
115	BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy. Cancer Chemotherapy and Pharmacology, 2014, 73, 771-778.	2.3	22
116	The PI3K/AKT/MTOR Signaling Pathway: The Role of PI3K and AKT Inhibitors in Breast Cancer. Current Breast Cancer Reports, 2014, 6, 59-70.	1.0	7
117	ASCO 2014: highlights in breast cancer. Memo - Magazine of European Medical Oncology, 2014, 7, 242-245.	0.5	0
118	Improved Differentiation of Benign and Malignant Breast Tumors with Multiparametric 18Fluorodeoxyglucose Positron Emission Tomography Magnetic Resonance Imaging: A Feasibility Study. Clinical Cancer Research, 2014, 20, 3540-3549.	7.0	82
119	Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. Breast, 2014, 23, 637-643.	2.2	56
120	Alleviation of Brain Edema and Restoration of Functional Independence by Bevacizumab in Brain-Metastatic Breast Cancer: A Case Report. Breast Care, 2014, 9, 134-134.	1.4	25
121	Association of <i>TP53</i> codon 72 polymorphism with <i>TP53</i> mutation in triple-negative breast cancer (TNBC) patients.. Journal of Clinical Oncology, 2014, 32, 1130-1130.	1.6	1
122	Association of tumor-infiltrating lymphocytes with brain edema and overall survival in brain metastases.. Journal of Clinical Oncology, 2014, 32, 2012-2012.	1.6	1
123	A cross-section study evaluating patients' satisfaction with totally implanted access ports (PAC) assessing the PAC-related complication rate at two tertiary care centres in Austria.. Journal of Clinical Oncology, 2014, 32, e17574-e17574.	1.6	1
124	Indocyanine Green Video Angiography Predicts Outcome of Extravasation Injuries. PLoS ONE, 2014, 9, e103649.	2.5	9
125	Effect of multiparametric MRI of the breast on diagnostic accuracy.. Journal of Clinical Oncology, 2014, 32, 11009-11009.	1.6	0
126	ASCO 2013: news in early-stage and advanced breast cancer. Memo - Magazine of European Medical Oncology, 2013, 6, 227-232.	0.5	0



#	ARTICLE	IF	CITATIONS
127	Optimal Management of Brain Metastases from Breast Cancer. <i>CNS Drugs</i> , 2013, 27, 121-134.	5.9	27
128	Primary systemic treatment of breast-cancer brain metastases. <i>Lancet Oncology</i> , The, 2013, 14, 8-9.	10.7	1
129	Impact of Her-2-Targeted Therapy on Overall Survival in Patients With Her-2 Positive Metastatic Breast Cancer. <i>Breast Journal</i> , 2013, 19, 149-155.	1.0	17
130	Antiangiogenic treatment approaches in breast cancer. <i>Breast Cancer Management</i> , 2013, 2, 397-406.	0.2	0
131	Molecular subtyping of breast cancer using dedicated breast PET-CT.. <i>Journal of Clinical Oncology</i> , 2013, 31, e22090-e22090.	1.6	0
132	Influence of the American ODAC Statement on Austrian Bevacizumab Prescribing Practice for Metastatic Breast Cancer. <i>Oncologist</i> , 2012, 17, e13-e17.	3.7	7
133	Axillary Dissection in the Case of Positive Sentinel Lymph Nodes: Results of the Innsbruck Consensus Conference. <i>Geburtshilfe Und Frauenheilkunde</i> , 2012, 72, 293-298.	1.8	2
134	Brain metastases free survival differs between breast cancer subtypes. <i>British Journal of Cancer</i> , 2012, 106, 440-446.	6.4	74
135	Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. <i>British Journal of Cancer</i> , 2012, 106, 25-31.	6.4	68
136	Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. <i>European Journal of Cancer</i> , 2012, 48, 1932-1938.	2.8	47
137	What's new in metastatic breast cancer?. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 110-115.	0.5	0
138	Correlation of large brain edema with favorable prognosis in patients with single brain metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2053-2053.	1.6	0
139	Trends and Novel Approaches in Neoadjuvant Treatment of Breast Cancer. <i>Breast Care</i> , 2011, 6, 427-433.	1.4	4
140	Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial. <i>BMC Cancer</i> , 2011, 11, 373.	2.6	22
141	Locally advanced gastric cancer treated with neoadjuvant chemotherapy: Epirubicin, oxaliplatin, and capecitabine (EOX).. <i>Journal of Clinical Oncology</i> , 2011, 29, 136-136.	1.6	0
142	Triple-negative breast cancer. <i>Wiener Medizinische Wochenschrift</i> , 2010, 160, 174-181.	1.1	26
143	The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment &ndash; Current and Future Tools. <i>Breast Care</i> , 2009, 4, 167-176.	1.4	4
144	Role of denosumab in breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 1225-1233.	3.1	7

#	ARTICLE	IF	CITATIONS
145	Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer. <i>BMC Cancer</i> , 2009, 9, 367.	2.6	22
146	The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 373-380.	2.5	9
147	Predicting response to second-line trastuzumab-based therapy in patients (pts) with HER2-positive advanced breast cancer (ABC). <i>Journal of Clinical Oncology</i> , 2009, 27, 1090-1090.	1.6	1
148	Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 903-910.	2.3	42
149	Adjuvant chemotherapy in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2008, 1, 91-98.	0.5	2
150	Her2 and Progesterone Receptor Status Are Not Predictive of Response to Fulvestrant Treatment. <i>Clinical Cancer Research</i> , 2007, 13, 4435-4439.	7.0	20
151	Capecitabine and Trastuzumab in Heavily Pretreated Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3853-3858.	1.6	144
152	HER-2-Positive Breast Cancer. <i>BioDrugs</i> , 2007, 21, 69-77.	4.6	30
153	Expression of thymidine phosphorylase in peripheral blood cells of breast cancer patients is not increased by paclitaxel. <i>BMC Clinical Pharmacology</i> , 2007, 7, 7.	2.5	2
154	Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. <i>Journal of Neuro-Oncology</i> , 2007, 85, 311-317.	2.9	127
155	Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007, 102, 375-381.	2.5	29
156	Trastuzumab (T) plus capecitabine (C) in heavily pretreated patients (pts) with advanced breast cancer (ABC). <i>Journal of Clinical Oncology</i> , 2007, 25, 1055-1055.	1.6	0
157	Trastuzumab in the management of early and advanced stage breast cancer. <i>Biologics: Targets and Therapy</i> , 2007, 1, 19-31.	3.2	33
158	Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer – A retrospective analysis. <i>Radiotherapy and Oncology</i> , 2006, 80, 313-317.	0.6	39
159	Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 554-558.	2.3	24
160	Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study. <i>BMC Cancer</i> , 2006, 6, 63.	2.6	49
161	Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment. <i>BMC Cancer</i> , 2006, 6, 81.	2.6	21
162	Intensified local treatment and systemic therapy significantly increase time to progression and survival in patients with brain metastases from advanced breast cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 10536-10536.	1.6	0

#	ARTICLE	IF	CITATIONS
163	Serum interleukin-6 levels in patients with gastric MALT lymphoma compared to gastric and pancreatic cancer. <i>Anticancer Research</i> , 2006, 26, 3187-90.	1.1	8
164	Darbepoetin ?? as treatment for anemia in patients receiving chemotherapy: a single-center experience. <i>Anti-Cancer Drugs</i> , 2005, 16, 617-620.	1.4	5
165	Retrospective analysis of re-irradiation in malignant glioma: a single-center experience. <i>Wiener Klinische Wochenschrift</i> , 2005, 117, 821-826.	1.9	13
166	Fulvestrant (â€ˆFaslodexâ€™™) in pre-treated patients with advanced breast cancer: A single-centre experience. <i>European Journal of Cancer</i> , 2005, 41, 2655-2661.	2.8	39